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Tuberous sclerosis complex (TSC) is a tumor suppressor syn-
drome caused by mutations in TSC1 or TSC2, encoding hamar-
tin and tuberin, respectively. These proteins act as a complex
that inhibits mammalian target of rapamycin (mTOR)-medi-
ated cell growth and proliferation. Loss of either protein leads
to overgrowth in many organs, including subependymal nod-
ules, subependymal giant cell astrocytomas, and cortical tubers
in the human brain. Neurological manifestations in TSC
include intellectual disability, autism, hydrocephalus, and epi-
lepsy. In a stochastic mouse model of TSC1 brain lesions, com-
plete loss ofTsc1 is achieved in homozygousTsc1-floxedmice in
a subpopulation of neural cells in the brain by intracerebroven-
tricular (i.c.v.) injection at birth of an adeno-associated virus
(AAV) vector encoding Cre recombinase. This results in me-
dian survival of 38 days and brain pathology, including
subependymal lesions and enlargement of neuronal cells.
Remarkably, when these mice were injected intravenously on
day 21 with an AAV9 vector encoding hamartin, most survived
at least up to 429 days in apparently healthy condition with
marked reduction in brain pathology. Thus, a single intrave-
nous administration of an AAV vector encoding hamartin
restored protein function in enough cells in the brain to extend
lifespan in this TSC1 mouse model.
INTRODUCTION
Tuberous sclerosis complex (TSC) is an autosomal-dominant, tumor
suppressor disorder caused by an inherited or de novo mutation in
one allele of TSC1 (encoding hamartin) or TSC2 (encoding tuberin),
which affects 2 million people worldwide with an incidence of 1/6,000
live births.1 Hamartin and tuberin act as a complex with Tre2-Bub2-
Cdc16 (TBC) 1 domain family, member 7 (TBC1D7) with Rheb-GAP
activity to inhibit mammalian target of rapamycin complex 1
(mTORC1), which in turn regulates cell growth and proliferation.2
Mutation of the corresponding normal allele of TSC1 or TSC2 in so-
matic cells leads to hamartoma (tumor) development inmany organs,
including brain, heart, kidneys, skin, and lungs.3,4 Most TSC patients
have neurological involvement (95%), including cortical tubers, sub-
ependymal nodules (SENs), and subependymal giant cell astrocy-
tomas (SEGAs), with symptoms including epilepsy (85%), autism
(40%), cognitive impairment (50%), and developmental delay
(70%).5 Rapamycin and rapalog therapy, which partially inhibits
mTORC1, has been shown to be effective for several aspects of TSC
pathophysiology, but may interfere with normal brain development,
including neuronal growth, axon guidance, synapse formation, and
myelination.6,7 Furthermore, rapalog therapy must be continuous
or growth of lesions will resume.
In previous studies, we demonstrated that a single intracerebroven-
tricular (i.c.v.) injection of an adeno-associated virus (AAV) serotype
rh8 vector encoding human hamartin under the cytomegalovirus
(CMV) promoter8 into pups at post-natal day (P) 0 could effectively
rescue neurodevelopment and extend survival from a mean of
22–52 days in offspring of homozygous Tsc1c/cROSA (hereafter
referred to as Tsc1-floxed) expressing Cre under the synapsin pro-
moter.9 In this model, hamartin is lost in all brain neurons
commencing during development at embryonic day 12.10
In order to more realistically model brain lesions in TSC1 patients
that arise from loss of hamartin in a subset of cells of different types
in the brain, including neural precursor cells, neurons, astrocytes, and
subependymal cells, we developed a stochastic mouse model in which
loss of hamartin is random in a subpopulation of cells throughout the
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brain, and possibly in other parts of the body, starting at P0.11 This
model was achieved by i.c.v. injection of an AAV serotype 1 vector
encoding Cre recombinase under the constitutive chicken b-actin
(CBA) promoter8 into Tsc1-floxed pups at P0. We documented het-
erotopic brain lesions, enlarged neurons, and the formation of sube-
pendymal lesions and enlarged ventricles leading to hydrocephalus
and early death.11
Here we demonstrate the benefit of gene replacement in this stochas-
tic Tsc1-floxed mouse model. Tsc1 loss was induced in a subset of
neural cells by i.c.v. injection of AAV1-Cre at P0, and then these
mice were injected intravenously (i.v.) at P21 with AAV serotype
rh8 or 9 vectors encoding human hamartin under the CMV pro-
moter, or with a control vector or no vector. Behavior, survival,
neuropathology, and whole-body pathology were accessed. Advan-
tages of a gene replacement approach using AAVrh8 or AAV9
include the possible effectiveness of a single systemic injection of vec-
Figure 1. Schematic Representation of the Injection
Paradigms
(A) Landmarks such as sagittal and lambdoid sutures are
visible through the skin of a newborn pup (dotted lines).
The i.c.v. injection sites (black dots) were marked with a
non-toxic laboratory pen. (B) i.c.v. injection was made
using a finely pulled glass pipette. (C) For i.v. injections, the
needle was inserted, bevel down, at the medial canthus,
into the retro-orbital sinus. (D) Diagram shows correct
placement of the needle relative to the retro-orbital sinus,
the eyeball, and the back of the orbit.
tor, low toxicity, extensive biodistribution, and
ability to cross the blood-brain barrier
(BBB).12,13
RESULTS
The vector used for hamartin delivery has AAV2
inverted terminal repeats (ITRs) and human ha-
martin cDNA tagged with a c-Myc epitope under
a CMVpromoter.9 A parallel construct encoding
GFP was used as a control.14 The plasmid con-
structs were transfected into HEK293 cells, and
cell lysates were used for western blots showing
a band corresponding to hamartin-c-Myc
(135 kDa) using antibodies to either hamartin
or c-Myc.9 These constructs were then packaged
in either AAVrh8 or AAV9 capsids. i.c.v. injec-
tion of the AAV1-CBA-Cre vector (Figures 1A
and 1B) was performed in newborn pups, fol-
lowed by i.v. injection of the AAV-CMV-hamar-
tin vector into the retro-orbital vasculature at P21
(Figures 1C and 1D).
In the first set of experiments, homozygous
Tsc1-floxed P0 pups were injected i.c.v. with
AAV1-Cre, using 2 mL containing 9.6  109 genome copies (g.c.),
into each ventricle (total of 1.9  1010 g.c.). These mice were injected
i.v. on P21 with 60 mL total volume of AAVrh8-hamartin (10 mL con-
taining 2  1010 g.c. + 50 mL saline; n = 12) or AAVrh8-GFP (1 mL
containing 1.2 1010 g.c. + 50 mL saline; n = 12) into the retro-orbital
vasculature behind one eye or received no injection (n = 5). The g.c.
ratio of i.c.v. to i.v. AAV was about 1:6. Average survival time for the
AAVrh8-GFP-injected or non-i.v.-injectedmice was 47 days, whereas
mice injected with AAVrh8-hamartin had extended average survival
to 156 days (p < 0.0001) (Figure 2A). Over 40 days after P0 AAV1-Cre
i.c.v. injection, Tsc1-floxed mice had enlarged heads indicative of
brain hydrocephalus and hunched backs associated with distress, as
compared with those subsequently treated with i.v. AAV-hamartin,
which appeared similar to normal mice (n = 5/group; Figure S1).
No signs of overt epilepsy were observed in handling the mice. In
both sets of experiments (one set injected with AAVrh8-hamartin
and the other set injected with AAV9-hamartin at P21), mice from
www.moleculartherapy.org
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each group (n = 3/group) were examined at P37 by a rodent
pathologist (R.T.B.), and no pathology was observed in any organs
throughout the body.
In a second set of experiments, Tsc1-floxed pups were injected i.c.v.
with AAV1-Cre, using 2 mL containing 1.6  1010 g.c., into each
ventricle (total of 3.2  1010 g.c.) at P0. AAV-Cre-injected mice
that did not receive an i.v. vector injection (n = 13) died on average
by day 32. Most mice subsequently injected i.v. at day 21 with a total
volume of 60 mL AAV9-hamartin (10 mL containing 2.4 1011 g.c. +
50 mL saline; n = 13) into the retro-orbital vasculature behind one eye
lived over 400 days (at least a 10-fold increase in survival time), at
which point they were sacrificed for pathology (Figure 2B, arrow).
The g.c. ratio of i.c.v. to i.v. AAV was about 1:7.5. All mice that did
not receive the AAV-Cre injection at P0 but did receive the AAV9-ha-
martin in a total volume of 60 mL (10 mL containing 2.4  1011 g.c. +
50 mL saline; n = 6) lived up to at least 450 days, supporting low-to-no
toxicity of this hamartin vector (Figure 2B). Because the AAV9 vector
appeared to be more effective than the AAVrh8 vector in extending
lifespan in this Tsc1 model, we used AAV9 for subsequent
experiments.
In the next set of experiments, Tsc1-floxed pups were injected i.c.v.
with AAV1-Cre, using 2 mL containing 1.8  1011 g.c., into each
ventricle (total of 3.6  1011 g.c.) at P1 (n = 13). At P21, half of
the mice were injected with AAV9-hamartin (20 mL containing
1.5  1012 g.c. + 40 mL saline; n = 7) into the retro-orbital vascula-
ture behind one eye, and the other half of mice were non-injected.
These mice at P23 were subjected to body weight measurement and
motor function assessment (n = 5 for naive group [male = 2;
female = 3], n = 6 for AAV1-CBA-Cre injection at P1 [male = 2;
female = 4], n = 7 for AAV1-Cre injection at P1 and AAV9-hamar-
tin injection at P21 [male = 3; female = 4]). Body weights of the an-
imals were recorded over the period of P23–P43 with similar rates
of weight gain in all groups (Figure 2C). Movement was assessed us-
ing an automated rotarod apparatus using accelerated (4–64 rpm
over 120 s) velocities. A significant decreased time to fall off the ro-
tarod (latency) was observed for the AAV1-Cre-injected mice as
compared with the AAV1-Cre+AAV9-hamartin and control mice
(Figure 2D).
Neuropathological examination of mouse brains from the experi-
ments revealed enlarged ventricles and clumping of subependymal
cells, suggesting proliferation, in many areas around the ventricles
on day 37 after i.c.v. AAV1-Cre injection of Tsc1-floxed pups (Figures
3B and 3E), as compared with normal non-injected mice (Figures 3A
and 3D). Brain pathology in the former was resolved following P21
i.v. injection of the AAV9-hamartin vector (Figures 3C and 3F). Im-
munostaining with Ki67 of the mouse brains (Figures 4A–4C),
mounted using DAPI counterstain media (Figures 3D–3F), revealed
more proliferating cells in the ependymal and subependymal layers
around the ventricles, with some moving away from the ventricles
on day 43 after i.c.v. AAV-Cre injection of Tsc1-floxed pups (Fig-
ure 4B), as compared with normal non-injected mice (Figure 4A)
or mice injected with the AAV1-Cre vector followed by the AAV9-
hamartin vector (Figure 4D).
Figure 2. Gene Replacement and Survival of Tsc1-
FloxedMice Injected with AAV-Cre Vectors with and
without AAV-Hamartin Vectors, Including Body
Weight and Rotarod Assessments
(A) Homozygous Tsc1-floxed pups received i.c.v. injection
into both cerebral ventricles at P0 using the AAV1-Cre
vector. At P21 in four separate experiments, mice were
randomly assigned into three groups for retro-orbital in-
jections (group 1 = mice injected with AAVrh8-hamartin
[n = 12]; group 2 = mice injected with AAVrh8-GFP
[n = 12]; group 3 = no injection [n = 5]). Log-rank (Mantel-
Cox) survival curves were 156, 46, and 47 days for groups
1, 2, and 3, respectively. A highly significant difference,
p < 0.0001 (log-rank test; GraphPad Prism), was found
when comparing group 1 with groups 2 and 3. (B) Ho-
mozygous Tsc1-floxed pups received i.c.v. injection into
both cerebral ventricles at P0 using the AAV1-Cre vector.
At P21 days, in three separate experiments mice were
randomly assigned to three groups for retro-orbital in-
jections (group 1 = AAV-Cre + AAV9-hamartin [n = 13];
group 2 = no injection [n = 13]). Another set of mice
(group 3) was injected with only AAV9-hamartin at
P21 days with no Cre injection (n = 6). Mean survival, based on log-rank (Mantel-Cox) survival curves, in the different groups was 429, 32, and >450 days for groups 1, 2,
and 3, respectively. Black arrow indicates whenmice were sacrificed. A highly significant difference, p < 0.0001 (log-rank test, GraphPad Prism), was found when comparing
groups 1 and 2. Groups 1 and 3 were also significantly different, p < 0.005. (C) Tsc1-floxedmice injected with AAV1-Cre vector with (n = 7) and without (n = 6) AAV9-hamartin
vector showed normal weight gain as compared with naive mice (n = 5). (D) At an accelerated speed of 4–64 rpm for the rotarod test, the motor function of the Tsc1-floxed
mice rescued by AAV9-hamartin vector was similar to the control and significantly decreased as compared with the AAV1-Cre-only group. ***p < 0.001; ****p < 0.001 (two-
way ANOVA test).
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The average increase in neuronal cell size in the brain resulting from
i.c.v. AAV1-Cre injection (Figure 5B) was restored to normal size
(Figure 5A) after i.v. injection of AAV9-hamartin at P21, as assessed
on P37 (Figure 5C). This histological observation was further sup-
ported by data quantified blindly by measuring neuronal cell area
and perimeter (Figure 5D), with H&E-stained neurons identified in
cortical sections as having a prominent nucleolus within a pale stain-
ing nucleus and cytoplasm.15 Phosphorylation of S6 is upregulated in
TSC-deficient cells as a result of loss of hamartin and increase in
mTORC1 activity.9 In the present study, elevated pS6 immunostain-
ing was evaluated in the cerebral cortex of AAV1-Cre injected Tsc1-
floxed pups (Figure S2B), as compared with AAV9-hamartin-injected
mice (Figure S2C) and normal controls (Figure S2A). Quantitative
analysis of pS6 staining was carried out by blinded scoring of staining
intensity. Although there was a trend for lower staining intensity in
non-injected and AAV-Cre/AAV9-hamartin mice as compared
with AAV-Cre-only-injected mice, the difference among groups
was not significant (Figure S2D).
In order to assess the extent and types of cells in the brain in which
the AAV1-mediated delivery of Cre-recombinase might lead
to loss of hamartin, we used the floxed reporter mouse
[Gt(ROSA)26Sortm9(CAG-tdTomato)Hze], which was injected with 2 mL
containing 1.8  1011 g.c. (total of 3.6  1011 g.c.) AAV1-CBA-Cre
i.c.v. into each ventricle of P1 pup. At P21, the animals were eutha-
nized, and red fluorescent cells were evaluated by fluorescent micro-
scopy (Figure S3A). Extensive delivery was noted throughout the
brain, including cells with the morphology of neurons (yellow arrow-
head, Figure S3A0) and astrocytes (white arrowhead, Figure S3A0) in
the cerebral cortex (Figure S3A0), cells in the hippocampus (Fig-
ure S3A00), as well as cells adjacent to the ventricular region (Fig-
ure S3A00). In order to investigate the efficiency of i.v. delivery of
AAV9, AAV9-CBA-GFP (1.8  1011 g.c. in 60 mL) was administered
into the retro-orbital vein of P21 pups. Two weeks later, the animals
were sacrificed, and GFP-positive cells were studied. We observed
efficient delivery of virus vector in which GFP-positive cells were
found throughout the brain including those appearing to be neurons
(yellow arrowhead, Figure S3B0) and astrocytes (white arrowhead,
Figure S3B0), hippocampal cells (Figure S3B00), as well as cells in prox-
imity to the ventricular region (Figure S3B00).
DISCUSSION
This study demonstrates the remarkable ability of a single i.v. injec-
tion of an AAV-hamartin vector to substantially extend the lifespan
of homozygous Tsc1-floxed mice that have lost hamartin in a subset
of neural cells throughout the brain starting from birth due to an
i.c.v. injection of AAV1-Cre. This stochastic loss of hamartin in the
mouse brain leads to enlarged neurons, cortical heterotopias, SEN-
like overgrowths of the subependymal layer of the ventricles, enlarged
ventricles, and hydrocephalus, with hydrocephalus thought to
contribute to early death.11 Using two different serotypes of AAV,
rh8 and 9, both of which can enter the brain following i.v. administra-
tion,12,13 an i.v. injection of AAV-hamartin at P21 extended the life-
span of most of these mice an average of 156 and over 429 days,
respectively, with a normal lifespan of these mice being about
650 days. Extended lifespan was accompanied by resolution of sub-
ventricular overgrowths and reduction in size of ventricles, return
of most neuronal cells in the brain to a normal size, and apparent
normalization of levels of S6 phosphorylation in the brain. One of
the advantages of this gene therapy approach is that the cDNA for
Figure 3. H&E Staining of Tsc1-Floxed Brains
(A–F) Coronal section of the fourth (4th V) (A–C) and third ventricles (3rd V) (D–F). (A and D) Coronal sections of normal non-injected Tsc1-floxed brains at P37 showed normal-
sized ventricles (A) and the subependymal layer (D). (B and E) Tsc1-floxed mice injected i.c.v. with AAV1-Cre on P0 exhibited enlarged ventricle, indicating incipient hy-
drocephalus (B) and cell clumping, indicating overgrowth of subependymal cells lining the ventricle (E, inset: arrowheads showing the higher magnification of clumping of
subependymal cells). (C and F) Tsc1-floxed mice injected i.c.v. with AAV1-Cre on P0, then retro-orbitally injected with AAV9-hamartin at P21 showed normal ventricular size
(C) and a single subependymal layer of cells surrounding the ventricles (F). Original magnification, 10. Scale bars, 200 mm.
www.moleculartherapy.org
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full-length hamartin is 3.5 kb, and thus fits easily into the 4.6-kb ca-
pacity of an AAV vector as a self-complementary vector that provides
robust transgene expression.16 In addition, a single injection, some-
time after the disease course has been set, suffices for a remarkable
extension of lifespan. AAV9 vectors in clinical trials for neurological
diseases in humans are showing long-term benefits with low-to-no
adverse effects.17 Because TSC1/hamartin is thought to function
largely, if not exclusively, in a complex with TSC2/tuberin and
TBC1D7,18 and levels of tuberin are normal in these mice, overex-
pression of hamartin was predicted to have no adverse effects, and
none were noted.
Current treatment for symptoms of TSC is based on rapamycin ana-
logs that inhibit mTORC1 activity. Although these analogs are effec-
tive for some symptoms, they require continuous treatment, have
reduced access to the brain from the periphery,19 compromise
immune function,20–22 and may interfere with neuronal
development.23,24 AAV vectors have recently become a clinical prod-
uct for treatment of eye disease (Luxturna; Spark Therapeutics) and
spinal muscular atrophy (Zolgensma; Novartis), and they hold great
promise for single application benefit in patients with hereditary
diseases caused by loss of protein function. In the case of gene replace-
ment of hamartin, there appears to be no toxic effect on cells express-
ing normal levels of hamartin, probably because hamartin needs to
complex with tuberin to be active and is therefore titrated by the
normal levels of tuberin present in Tsc1-floxed cells.
Clinical trials with the AAV-hamartin vector may be facilitated by
the fact that reduction in size of SENs should be relatively rapid
and can be monitored by MRI.25,26 Subependymal nodule can
expand into SEGAs and occur in 10%–15% of TSC children, usually
appearing after birth.25,26 These can enlarge over the first decade of
life, causing obstruction of cerebrospinal fluid flow, leading to life-
threatening hydrocephalus, as well as endocrinopathy and visual
impairment. Under optimal care, TSC infants and children are moni-
tored for subependymal lesions by MRI every 6–12 months. The two
current standard of care procedures are neurosurgical removal of the
SEGA through craniotomy, which is associated with significant
morbidity,26 or treatment with the rapamycin analog, everolimus,
which has concerns, especially in children for whom arguably it
may interfere with normal brain development. In development, the
hamartin and tuberin complex serves to regulate the mTORC1
pathway, which is critical to neuronal growth, axon guidance, syn-
apse formation, and myelination.6,7,24 Increased mTOR activity has
also been associated with ectopic neuronal differentiation, enlarged
neurons with increased dendritic complexity, defects in neuronal
migration and cortical malfomations.7,27 On the other hand, inhibi-
tion of mTOR by rapamycin appears to contribute to the observed
memory dysfunction in the prenatal and post-natal drug treatment
in Tsc mouse models23 and the behavioral abnormalities in wild-
type mice treated prenatally with rapamycin.6 Further, rapamycin
treatment for TSC lesions must be continuous or lesions will resume
growth. Alternately, because AAV9 and AAVrh8 vectors cross the
BBB, the AAV-hamartin vector could be administered i.v., as has
been done to rescue motor neurons in spinal muscular atrophy pa-
tients.28 This could have the added advantage of providing extra
levels of hamartin in heterozygous TSC1 cells, which might, in
turn, reduce the effects of a subsequent somatic mutation in the
normal TSC1 gene, leading to growth of lesions in the brain and in
other parts of the body. It is hoped that gene replacement therapy
may reduce use of current problematic standard of care procedures
in young children with TSC1 and provide long-lasting benefit. This
AAV-mediated gene therapy could also be combined with rapamycin
therapy for lesions arising later in life.
Figure 4. Ki67 Immunostaining of Tsc1-Floxed Brains
(A–C) Tsc1-floxed mice injected with AAV1-Cre vectors only showmore proliferating cells adjacent to the lateral ventricular area (B) as compared with the naive group (A) and
the Tsc1-floxed mice rescued by AAV9-hamartin vectors (C). Yellow arrows indicate the proliferating Ki67+ve cells some distance away from the ventricular layer. The
corresponding brain sections were counterstained with DAPI (D–F). Original magnification, 20. Scale bar, 100 mm. CC, corpus callosum; LV, lateral ventricle.
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Conclusions
In this preclinical study of gene replacement therapy in a mouse
model of TSC1, AAV vectors that cross the BBB, such as serotypes
rh8 and 9, encoding hamartin were able to increase survival time
by at least 3-to 13-fold. Increase in survival was accompanied by
normalization of sizes of ventricles and neural cell bodies in the brain.
MATERIALS AND METHODS
AAV Vector Design and Packaging
AAV vector plasmid, AAV-CBA-Cre-BGHpA, was derived from the
plasmid AAV-CBA-EGFP-W14 by replacing EGFP and Woodchuck
hepatitis virus (WHP) posttranscriptional regulatory element
(WPRE) element with cDNA encoding Cre recombinase. The
AAV-CBA-GFP-W vector was used as a control. The CBA promoter
is composed of the CMV immediate or early gene enhancer fused to
the b-actin promoter.8 The dsCMV-hamartin-c-Myc plasmid was
derived from the double-stranded AAV (dsAAV)-CBA-BGHpA.
This plasmid carries two AAV2 ITR elements, one wild-type and
one in which the terminal resolution site was deleted, as described
previously,14 generating a vector that is packaged as a double-
stranded molecule. This AAV-CMV-hamartin-c-Myc construct9
was generated by replacing the CBA promoter in the parent plasmid
with PCR-amplified CMV promoter using a lentivirus vector
construct29 as a template and the following primers: CMV-1: 50-AAA
GGTACCGATTAATAGTAATCAATTACGGGGT-30 and CMV-2:
50-AGCGCTAGCGGATCTGACGGTTCACT-30 inserted in be-
tween KpnI and NheI sites. Human hamartin cDNA was PCR
amplified using the original human hamartin plasmid TSC1-
FLAGpcDNA30 as a template and the following primers: hamartin-1:
50-AAAGCTAGCGCCACCATGGCCCAACAAGCAAATGTCGG
GGA-30 and hamartin-2: 50-AAAAGCGGCCGCTTAGCTGTGTT
CATGATGAGTCTCATTG-30 and inserted in between NotI and
SacI sites. The c-Myc epitope was added in-frame at the C terminus
by using the following primer: 50-AAGCGGCCGCTCACAGG
TCCTCCTCGCTGATCAGCTTCTGCTCGCTGTGTTCATGATG
AGTCTCATTG-30.
AAVrh8, AAV9, and AAV1 serotype vectors were produced by tran-
sient co-transfection of 293T cells by calcium phosphate precipitation
of vector plasmids (AAV-CMV-hamartin) or Cre,14 adenoviral helper
plasmid pFD6, and a plasmid encoding AAVrh8 (pAR-rh8), AAV9
(pXR9), or AAV1 (pXR1) capsid genes, as previously described.14 All
AAV vectors carried the bovine growth hormone polyadenylation
signal. The identity of all PCR-amplified sequences was confirmed by
sequencing. In brief, AAV vectors were purified by iodixanol gradient
centrifugation followed by column chromatography using HiTrapQ
anion exchange columns (GEHealthcare, Piscataway,NJ,USA). The vi-
rus-containing fractions were concentrated using Centricon 100-kDa
molecularweight cut-off (MWCO) centrifugal devices (EMDMillipore,
Billerica,MA,USA), and the titer (g.c./mL)was determinedby real-time
PCR amplification with primers and a probe specific for the bovine
growth hormone polyadenylation (BGH polyA) sequences.
Animals and Injections
Experimental researchprotocolswere approvedby the InstitutionalAn-
imal Care and Use Committee (IACUC) for theMassachusetts General
Figure 5. H&E Staining of Brain Sections and Measurement of Diameter of the Neurons
(A and C) Normal size of neurons (green arrows) was observed in the cerebral cortical region above the lateral ventricles on P37 in non-injected Tsc1-floxed mice (A) and in
AAV1-Cre (P0) and AAV9-hamartin (P21) vector-injected mice (C). (B) Large neurons (red arrows) were observed in the brains injected with AAV-Cre only. Original
magnification,40. Scale bars, 20 mm. (D) The perimeter (mm) and area size (mm2) of randomly selected neuronal cell bodies weremeasured in 540 neurons in the cortex from
several fields with three animals per group, and the observer was blinded to group status. Data are shown as mean ± SEM (***p < 0.001; ****p < 0.0001).
www.moleculartherapy.org
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Hospital (MGH) following the guidelines of the NIH’s Guide for the
Care and Use of Laboratory Animals. Experiments were performed on
Tsc1c/c mice (Tsc1-floxed), which also carried the Cre-inducible
ROSA26 lacZ marker allele, as described previously.10,31 In response
to Cre recombinase, the Tsc1c/c alleles are converted to null alleles.
These Tsc1-floxed mice have a normal lifespan. For i.c.v. vector injec-
tions, shortly after birth (P0–P3) neonates were cryo-anesthetized
and injected with 2 mL viral vector AAV1-CBA-Cre into each cerebral
lateral ventricle with a glass micropipette (70–100 mm in diameter at
the tip) using a Narishige IM300 microinjector at a rate of 2.4 psi/s
(Narshige International, East Meadow, NY, USA). Mice were then
placed on a warming pad and returned to their mothers after regain-
ing normal color and full activity typical of newborn mice.
For retro-orbital injections, at 3 weeks of age (P21) mice were anes-
thetized with isoflurane inhalation (3.5% isoflurane in an induction
chamber and then maintained anesthesia with 2%–3% isoflurane
and 1–2 L/min O2 for the duration of the experiment). AAV vectors
were injected retro-orbitally into the vasculature right behind one of
the eyeballs in a volume of 60 mL (10 mL AAVrh8 or AAV9-CMV-ha-
martin or AAVrh8-GFP and 50 mL 0.9% saline) using a 0.3-mL insu-
lin syringe over a 30-s to 2-min period.32
We also evaluated the efficiency of AAV1-mediated delivery of Cre-
recombinase to brain cells. P1 pups of the floxed reporter mouse
[Gt(ROSA)26Sortm9(CAG-tdTomato)Hze] were injected with 2 mL of
AAV1-CBA-Cre (1.8  1011 g.c.) via i.c.v. injection into each
ventricle. We further evaluated the efficiency of AAV9-mediated de-
livery of GFP to brain cells via i.v. injection. P21 pup of the C57/BL6
strain was injected with 60 mL AAV9-CBA-GFP (1.8  1011 g.c.) via
retro-orbital injection.
Body Weight Measurement and Functional Assessment of
Motor Activity
Mice at P23 consisting of both genders were subjected to body weight
measurement and motor function assessment (n = 5 for naive group
[male = 2; female = 3], n = 6 for AAV1-CBA-Cre injection at P1
[male = 2; female = 4], n = 7 for AAV1-CBA-Cre injection at P1
and AAV9-hamartin injection at P21 [male = 3; female = 4]). Sixteen
measurements of the body weight of the animals were recorded from
P23 to P43. To assess motor co-ordination, animals were placed on an
automated rotarod apparatus (Harvard Apparatus, Holliston, MA,
USA) using accelerated (4–64 rpm over 120 s) velocities. Each animal
was assessed three times with 5-min rest intervals in each session. In
each case, the experiment ended when the mouse fell off the treadmill
or when the total time elapsed. Seven measurements of the motor
function assessment of the animals were recorded from P23 to P43.
All functional assessment tests were performed blinded with respect
to the mouse genotype.
Histology and Immunohistochemistry (IHC) for Paraffin Sections
For standard histology, mice were first euthanized with CO2 fol-
lowed by immediate removal of brain and 2–4 days of fixation in
Bouin’s solution (VWR International, Radnor, PA, USA). Following
paraffin embedding, 5-mm sections were stained with H&E and
examined for full-body pathology by R.T.B., including chest, tra-
chea, lungs, heart, kidneys, spleen, pancreas, spinal cord, and repro-
ductive organ, using three mice per group. Five-micrometer coronal
sections from the brain were stained with H&E or were used for
IHC. Sections were deparaffinized in xylenes followed by re-hydra-
tion in decreasing ethanol concentrations. Endogenous peroxidase
was blocked with 3% hydrogen peroxide; then tissues were washed
in PBS. Heat-induced antigen retrieval was performed using sodium
citrate (10 mM, pH 6.0) in a 95C water bath for 10 min. Tissues
were blocked in 5% normal goat serum, then incubated with pri-
mary antibody pS6 235/236 (#2211; Cell Signaling, Danvers, MA,
USA) diluted 1:450, at 4C overnight. On the next day, the brain
sections were washed in Tris-buffered saline and Tween 20
(TBST) three times at 3-min intervals. Tissues were then incubated
with ready-to-use secondary antibody, SignalStain Boost IHC
Detection Reagent (#8114; Cell Signaling), at room temperature
(RT) for 30 min, and washed in TBST three times at 3-min inter-
vals. The sections were then incubated with DAKO horseradish
peroxidase (HRP)-compatible DAB (Vector Laboratories, Burlin-
game, CA, USA) for 3 min, washed with water, and then counter-
stained with hematoxylin, dehydrated, mounted, and preserved
with coverslips. Semi-quantitative analysis of pS6 staining intensity
in cerebral cortex was evaluated by a blinded observer on a scale of
0–3 (0 for no staining, 1 for light or weak staining, 2 for moderate
staining, and 3 for strong and intense staining). Brain sections were
stained for the c-Myc tag to detect transgene delivery but the cur-
rent lots of c-Myc antibody (#1667149, Roche Diagnostics) did
not detect a signal.
Neuronal Cell Measurements
H&E-stained brain sections were imaged on a Olympus microscope
at a magnification of 40, and images were captured from the ce-
rebral cortex above the lateral ventricles, as suggested by the pathol-
ogist (A.S.-R.), because these regions appeared to have the most
notable differences in size of the neurons as compared among these
sets of mice. The neurons were characterized by prominent nucle-
olus within the pale staining nucleus and the cytoplasm.15 Images
were examined using ImageJ. The perimeter (mm) and area size
(mm2) were measured for 540 randomly selected neurons from
several fields of the cerebral cortical region with three animals per
group by an observer blinded to status. Data are shown as
mean ± SEM (***p < 0.001; ***p < 0.0001).
Histology and IHC for Frozen Sections
Adult mice were euthanized using ketamine/xylazine (100:10) fol-
lowed by transcardiac perfusion with 1 PBS and 4% paraformalde-
hyde in PBS overnight at 4C, cryoprotected with 25% sucrose in PBS,
and embedded in tissue-embedding medium. Brain sections were
prepared in 10-mm coronal sections and were blocked in 10% BSA
in PBST (0.1 PBS+0.3% Triton X-100) for 1 h at RT and subse-
quently incubated with rabbit anti-Ki67 (#ab15580, 1:1,000; Abcam)
overnight at RT. Following three washes in 0.1 PBS, the sections
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were incubated with secondary antibodies for 1 h at RT. The sections
were then washed three times with 0.1 PBS andmounted with DAPI
mounting medium (Vectashield, #H-1200).
IHC for Free-Floating Brain Sections
To evaluate the efficiency of AAV1-mediated delivery of Cre-recom-
binase to brain cells, we injected P1 pups of the floxed reporter mouse
[Gt(ROSA)26Sortm9(CAG-tdTomato)Hze] (JAX#008848; Jackson Labs)33
with AAV1-CBA-Cre i.c.v. The pups were euthanized at P21 with
transcardiac perfusion with 1 PBS followed by 4% paraformalde-
hyde in PBS overnight at 4C, cryoprotected with 25% sucrose in
PBS, and embedded in optimal cutting temperature (OCT) tissue-
embedding medium. Free-floating brain sections were prepared as
40-mm coronal sections, and endogenous fluorescent signal was de-
tected using a tetramethylrhodamine isothiocyanate (TRITC) filter
with fluorescent microscopy.
We further evaluated the efficiency of AA9-mediated delivery of GFP
to brain cells via i.v. injection. P21 pups of the C57/BL6 strain were
injected with AAV9-CBA-GFP via retro-orbital injection. Two weeks
later, the animal was euthanized at P35 with transcardiac perfusion
with PBS followed by 4% paraformaldehyde in PBS for 48 h at 4C,
cryoprotected with 25% sucrose in PBS, and embedded in OCT tis-
sue-embedding medium. Free-floating brain sections were prepared
in 40-mm coronal sections and permeabilized with 0.5% Triton-X
in PBS. The sections were blocked in 5% normal goat serum in PBS
for 1 h at RT and subsequently incubated with GFP primary antibody
(#G10362, 1:400 dilution; Invitrogen) for 5 days at 4C on shaker.
Following three washes in PBS, the sections were incubated with sec-
ondary antibody (goat anti-rabbit IgG Alexa 488, #A-11034, 1:1,000
dilution) for 1 h at RT.
Statistical Analysis
All analyses of survival curves (chi-square test) were performed using
GraphPad Prism software (GraphPad Software, La Jolla, CA, USA).
The p values depicted are statistically significant. Diameter and
perimeter of the neurons were quantitatively analyzed using ImageJ
software and plotted in GraphPad Prism. One-way ANOVA followed
by Tukey’s post hoc test was used to evaluate statistical significance of
intensity levels of pS6 staining.
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